NEWS & Publications

Jenny Howell appointed Chief Operating Officer

Jenny Howell joins Thirty Group as Chief Operating Officer. Jenny has more than 20 years’ experience in the biotech and pharmaceutical industry, most recently with AstraZeneca/MedImmune where she held a number of senior leadership positions including Chief of Staff to...

read more

New 30Technology Research Centre opens in Oxford

Thirty Group is delighted to announce the opening of its new Research Centre at Milton Park, Oxford. The facility will house clinical, research, development and regulatory activities for our revolutionary 30Technology™ across Regenerative Medicine, Respiratory and...

read more

DR. JOHN EFTHIMIOU APPOINTED CHIEF MEDICAL OFFICER

John Efthimiou BSc MD FRCP is a respiratory specialist physician/scientist trained in London and Oxford teaching hospitals, accredited in both Respiratory and General Medicine. He joined Thirty Group in June 2019 and has over 25 years’ experience in and advising large...

read more

MORNINGSIDE VENTURES INVESTS IN THIRTY HOLDINGS

Thirty Holdings Limited completed a £25 million equity investment led by Morningside Ventures, a major investor in the global Life Science sector. The investment enables the Group to accelerate research and development. We are delighted to welcome Isaac Cheng to the...

read more

A NEW NAME FOR A NEW ERA

Thirty Holdings Limited established following a corporate restructure. The Company trading name will be 30 Technology with the name derived from the molecular weight of nitric oxide (30). Edixomed Limited is now a wholly owned subsidiary of Thirty Holdings, focusing...

read more

BREAKTHROUGH TECHNOLOGY

Breakthrough Technology to Prevent and Treat Antibiotic Resistant Infection New results announced at the recent Wounds UK conference and Eurobiofilms 2017 congress have provided the latest evidence that Edixomed, a UK biotechnology company, has developed a...

read more

US AND EU PATENTS GRANTED

Edixomed Granted US and EU Patent Protection for Their Nitric Oxide Generating Treatment System Edixomed have been granted Intellectual Property protection for their nitric oxide generating treatment system in both the EU and USA. The priority date for the patents is...

read more

ANTIMICROBIAL EFFECTIVENESS

Edixomed completes anti-microbial efficacy study An independent analysis performed by Perfectus Biomed and utilising the FDA stipulated AATCC Test Method 100-2004, indicates that the Company’s lead product has achieved the required bacterial and fungal reduction to...

read more

PILOT STUDY SUPPORT FOR CHILDREN IN AFRICA

Edixomed announced plans to support a pilot study using its innovative nitric oxide smart dressing system to treat Buruli ulcers, a debilitating skin condition affecting many thousands of children in West Africa and other parts of the world. According to the World...

read more

30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.

30 TECHNOLOGY Therapeutic Nitric Oxide